April 25: The Week in Cancer News
People with metabolic syndrome may have elevated risk for breast cancer mortality, and immunotherapy keeps lung cancer at bay even after discontinuing treatment.
Progress Against Cancer
People with metabolic syndrome may have elevated risk for breast cancer mortality, and immunotherapy keeps lung cancer at bay even after discontinuing treatment.
The FDA has approved penpulimab-kcqx for certain patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has approved penpulimab-kcqx in combination with chemotherapy for the first-line treatment of patients with nonkeratinizing nasopharyngeal carcinoma...
A recently approved first-line therapy and novel insights into optimizing treatment strategies may offer new options for esophageal cancer patients.
The test, which analyzes urine for 18 cancer-specific genes, ruled out the need for biopsy in men with elevated PSA without a digital rectal exam.
Gaps in goals-of-care discussions may harm young adults with cancer, and 1 in 6 participants in phase II trials get treatments that are eventually approved by the FDA.
A congressional forum hosted by Senators Tammy Baldwin and Peter Welch examined how NIH funding cuts could impact cancer and other diseases.
The FDA has approved nivolumab with ipilimumab as a first-line treatment for advanced liver cancer. The U.S. Food and Drug Administration (FDA) has approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the...
NIH layoffs delay research benefiting cancer patients, and celebrity cancer news is often missing important information.
The FDA has approved nivolumab with ipilimumab in certain patients with advanced colorectal cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the treatment of patients 12...
Some early-stage breast cancer patients may not need surgery, and FDA approves Imfinzi for muscle-invasive bladder cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More